TABLET FORMULATIONS OF VIABLE LACTIC ACID BACTERIA

Similar documents
Pharmaceutical Studies on Formulation and Evaluation of Sustained Release Tablets Containing Certain Drugs

DVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa, NJ

FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS

CHAPTER 8 HYDROGEL PLUG FORMULATION AND EVAUATION

Role of Food Matrix for Probiotic Effects

Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1

Tablet is a major category of solid dosage forms which are widely used worldwide. Extensive information is required to prepare tablets with good

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

A Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac

SUPER PROBIO OR... 1 capsule! 20 BILLION. 40 pots WORLDWIDE BACTERIA PER CAPSULE PRACTITIONER STRENGTH

Biopharmaceutics Dosage form factors influencing bioavailability Lec:5

PQRI Workshop Bethesda 2012

Formulation and Evaluation

Biacid: A EU approved natural growth promoter for Broilers

Effect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media

THE PRESENCE OF MICROORGANISMS IN SOME COMMON EXCIPIENTS USED IN TABLET FORMULATION

DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN

Available Online through Research Article

MODULATION OF GASTROINTESTINAL TRANSIT TIME OF SALBUTAMOL SULPHATE BY FLOATING APPROCHES

CONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications

Protection of dried probiotic bacteria from bile using bile adsorbent resins

COMPARISON OF SUBLINGUAL TABLETS WITH NITROGLYCERIN COMPLEXED WITH βñcyclodextrin OR TITRATED WITH CROSSPOVIDONE ñ TECHNOLOGICAL APPROACH

FORMULATION AND EVALUATION OF DILTIAZEM HYDROCHLORIDE COLON TARGETED TABLETS

Understanding probiotics and health

Formulation and evaluation of sublingual tablets of lisinopril

EVALUATION OF EFFERVESCENT FLOATING TABLETS. 6.7 Mathematical model fitting of obtained drug release data

ACID AND BILE TOLERANCE OF PROBIOTIC BACTERIA USED FOR LACTIC ACID FERMENTATION OF VEGETABLE JUICES

This PDF is available for free download from a site hosted by Medknow Publications

Designed and manufactured specifically for pharmaceutical capsule filling

[Type text] [Type text] [Type text]

Q What are Probiotics?

Biowaiver Study on Prednisolone Tablets 5 mg in Three Different Brands. Marketed in Sudan. Safaa Mohamed *, Tilal Elsaman

Challenges in Developing Stable and Efficient Probiotic Formulations

Hassan Pyar Kok-Khiang Peh *

Changes in the Microflora of Bovine Colostrum During Natural Fermentation

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

OPTIMIZATION OF CONTROLLED RELEASE GASTRORETENTIVE BUOYANT TABLET WITH XANTHAN GUM AND POLYOX WSR 1105

Colonization of the Porcine Gastrointestinal Tract by Lactobacilli

You can not see them but

Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS

MULTI-SPECIES DIRECT FED MICROBIAL SUPPLEMENT. Product Catalog June Cedar Falls Road Menomonie, WI

STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS

Assessing and Maintaining Probiotics in Food

Nutritional Management of the Racehorse. Laurie Lawrence, Ph.D. Department of Animal and Food Sciences University of Kentucky

Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig

Advantages and Limitations of In Vivo Predictive Dissolution (IPD) Systems

Best use of a probiotic supplement (Symprove TM )

New Studies Continue to Reveal the Health Benefits of Colostrum

PROBIOTICS are live microorganisms which, when ingested, confer a health benefits.

Safety assessment of pasteurised milk products fermented with Bacteroides xylanisolvens DSM 23964

Digestive Care Advisor Training #1. Digestion 101 & H.O.P.E.

Beta Glucan Synbiotic Formula Brief

Research Article. The effects of hyaluronic acid on the morphological physiological differentiation of Lactobacillus

PHARMACEUTICAL TECHNOLOGY REPORT. Abstract Summary. Introduction. Experimental Methods. Consumer Specialties ashland.com

Journal of Chemical and Pharmaceutical Research

For Adults and Children

Venkateswara Rao et.al Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online)

GSC CODEX MESSAGE CCFA48/2016/25

Study summaries L. casei 431

FORMULATION DEVELOPMENT AND EVALUATION OF COLON TARGETED DOSAGE FORM OF IBUPROFEN

Asian Journal of Pharmacy and Life Science ISSN Vol. 2 (2), July-Sept,2012

Design and In-vitro Evaluation of Silymarin Bilayer Tablets

1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small

The unlocked synergy of DFE Pharma MCC

TABLET DESIGN AND FORMULATION

DEVELOPMENT AND EVALUATION OF A DIRECTLY COMPRESSIBLE CO PROCESSED MULTIFUNCTION SUSTAINED RELEASE AGENT FOR TABLETS

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

Physiologically relevant in vitro methodology to determine true digestibility of carbohydrates and to predict the glycaemic response

Table 1. Coating Parameters

Sivakasi , Tamil Nadu, India. ABSTRACT KEYWORDS:

Development of Nutrient Delivery Systems: Ingredients & Challenges

Wettable Magnesium Stearate. What Are Customers Looking for in Selecting Pharmaceutical Lubricants?

PHARMACEUTICAL AID PREPARED BY B.KIRUTHIGA LECTURER DEPT OF PHARMACEUTICAL CHEMISTRY

MILK. Nutritious by nature. The science behind the health and nutritional impact of milk and dairy foods

Bahadur S. et al /J. Pharm. Sci. & Res. Vol.1(4), 2009,

Journal of Chemical and Pharmaceutical Research

Short Communication. Formulation of Furosemide Dispersible Tablets for Use in Paediatrics V. V. ABWOVA, P. N. MBEO, L. J. TIROP AND K. A. M.

Effect of dietary fiber on intestinal gas production and small bowel transit time in man13

Human Digestion. Junior Science

Microencapsulation of probiotic bacteria

Safety Assessment of Alginate-Konjac-Xanthan Polysaccharide Complex (PGX)

ANTIBACTERIAL TOOTHPASTE: DO NOT SWALLOW

COMPARATIVE IN VITRO EVALUATION OF COMMERCIALLY AVAILABLE PANTOPRAZOLE DELAYED RELEASE TABLETS

Re-compaction properties of lactose and microcrystalline cellulose

THE EFFECT OF SOME MICROORGANISMS IN GASTRO-INTESTINAL TRACTS ON THE NUTRITIVE VALUE OF BROILER DIETS

LAB.2. Tablet Production Methods

Department of Biotechnology, School of Life Sciences, Pondicherry University, Pondicherry , Índia. ABSTRACT

Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy

Effect of Polymer Concentration and Viscosity Grade on Atenolol Release from Gastric Floating Drug Delivery Systems

Influence of Different Prebiotics and Probiotics on Selective Intestinal Pathogens

7. SUMMARY, CONCLUSION AND RECOMMENDATIONS

Probiotic. Prebiotics:

International Journal of Medicine and Pharmaceutical Research

Lavanya Nutankalva,MD Consultant: Infectious Diseases

Opadry Enteric. Application Data. Drug Release from Acrylic-Based Opadry Enteric (94 Series) Coated Tablets INTRODUCTION MATERIALS AND METHODS

Probiotics Market Size, Share, Analysis, Growth, Trends, Outlook and Forecasts to 2024 Hexa Research

In-Vitro Starch and NDF Digestibility Using Rumen Fluid from Control and Bovamine Supplemented Cows

ENHANCEMENT OF SOLUBILITY OF BICALUTAMIDE DRUG USING SOLID DISPERSION TECHNIQUE

Evaluation of different binders for roller compaction R. Wang, W. Liu, T. Durig

Transcription:

Scientia Pharmaceutica (Sci. Pharm.) 69, 249-255 (2001) O Osterreichische Apotheker-Verlagsgeselischaft m. b. H., Wien, Printed in Austria TABLET FORMULATIONS OF VIABLE LACTIC ACID BACTERIA M. Stadler and H. Viernstein* Institute of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstrane 14, A- 1090, Vienna, Austria Summary The aim of this work was to develop a gastric juice-resistant tablet formulation of viable lactic acid bacteria (LAB). As excipients, hydroxypropyl-methylcellulose acetate succinate (HPMCAS) and sodium alginate were applied to enhance gastric juice-resistance, and~vicel~ was used to modify tablet disintegration in the intestine. The formulation was optimized using statistical experimental design methodology. The influence of the relevant process variables (amounts of excipients applied and compaction force) on the loss of viable cells during the tablet production, on acid stability, and on tablet disintegration time was investigated. It was found that the content of HPMCAS and the compaction force were the most important test variables for tablet preparation. They influence the loss of bacteria during the tableting process, gastric juice resistance, and the disintegration time of tablets after incubation in artificial intestinal fluid. ~vicel@ had little influence on all three test parameters, while sodium alginate only affected disintegration time in phosphate buffer ph 6.8. Keywords: lactic acid bacteria, matrix tablets Introduction Lactic acid bacteria (LAB) are a heterogeneous group of gram-positive rods and cocci that use carbohydrates as an energy source and produce lactic acid either as the sole product of metabolism or as the major end product. LAB present in the human and animal gut are introduced through fermented milk products, food and feed supplements, but also through pharmaceutical products'. LAB have been used to promote health for hundreds of years; their most obvious effect is the inhibition of pathogen growth in traditionally fermented food systems, accomplished primarily by the acidic nature of these cultures2. Stated health-promoting effects of LAB include improved absorption of nutrients, alleviation of lactose intolerance symptoms, metabolism of some drugs, reduction of serum cholesterol, decrease of enzymes implicated in carcinogen production, improvement of intestinal motility, stimulation of the immune system, and reduction of tumor incidence. The harmful effects of undesired bacteria can be overcome by establishing a new balance among the intestinal flora through ingestion of viable bacteria3. For a successfu1 implantation in the gastrointestinal tract, it is essential that bacteria survive stomach acidity. Due to the instability of LAB towards acid, they require protection during transit through the stomach. One possibility to avoid deterioration is incorporation of lyophilized LAB in lipophilic matriceshr coatings with fat or fat like materials5. Furthermore, mixtures of LAB and buffer substances, which raise the ph value of the gastric medium for a few hours after application, should facilitate the transit of viable bacteria from the stomach to the intestine6. Moreover, as in the present study bacteria can be embedded in acid resistant excipients, such as HPMCAS, by direct compression.

M. Stadler andh. Viernstein: Experimental Lyophilized LAB strain Luctobucillus acidophilus La-5 (~.ox~o''cfu/~) was supplied from Chr. Hansen BioSystems (Horsholm, Denmark), HPMCAS was purchased from Shin-Etsu Chemicals Ltd. (Tokyo, Japan), sodium alginate and ~vicel" from Fluka (Buchs, Switzerland). Microbial cell count determinations were done according to the Koch plate count technique7 using Rogosa ~ ~ from amerck r (Darmstadt, ~ Germany). Tablet processing was performed on an instrumented single punch tablet press (Korsch EKO, Berlin, Germany), under constant environmental conditions (35% R.H.; 20-22" C). Tablets were prepared biplan with a diameter of 10 mm. The loss of bacteria due to the tableting process was determined by calculation from numbers of viable cells in the mixed powders prior to compaction and in the tablets made therefrom. Artificial gastric juice (0.04N HCl) was used to evaluate the survival of LAB under acidic conditions using a dissolution tester (USP XXIV). For evaluation of the gastric juice resistance, tablets were incubated in 0.04N HC1 at 37" C for two hours, and the differences were determined of the microbial cell counts before and after treatment. Tablet disintegration time in intestinal fluid was studied by incubation in phosphate buffer (ph 6.8) using a dissolution tester (USP XXIV). An orthogonal central composite design9 was created to study the main effects and interactions of four factors on the loss of viable bacteria during tableting, on gastric juice-resistance, and on the disintegration time in the intestinal fluid. The factors investigated were the compaction force, and the contents of HPMCAS, ~vicel,@ and sodium alginate. Twenty seven experiments were required and the combinations were performed in random orders (Table 2). The dry weight of freeze dried bacteria was kept constant at 100 mg (3x10"~~~) per tablet. Sixteen runs represent the simple factorial design, and 8 the star points; the centre points were replicated three times. The axial distance (a) of the star points was 1.547. The independent variables and their experimental settings are listed in Table 1. Table 1 : Factors and levels investigated for tablet formulations of the orthogonal central composite design (formulations No. 1-27) Factor star low center h~gh star (-a) (-1) (0) (+I) (+a) compact~on- 4.3 10 20 30 35.5 force (kn) HPMC 84 125 200 275 316 (mg) Na-alginate 3.4 7.5 15 22.5 26.6 (ms) ~vicel" 6.8 15 30 40 53.2 (md Data analysis of the experimental design was performed using Statgraphics Plus for Windows 2.0 (Manugistics, Rockville, MD).

Tablet Formulations of Viable Lactic Acid Bacteria Table 2: Experimental settings and results of the central composite design kn HPMC Na- Av~cel tabl. 2h hours tmd alg. 0%) 0%) 20-2 I. 02 0. 13 6.0 10 125 7.5 15 0.44 0.83 2.5 30 125 7.5 15 1.04 0.32 2.75 10 275 7.5 15 0.82 0.32 6.0 30 275 7.5 15 1.13 0.12 7.5 10 125 22.5 15 0.38 0.88 3.0 30 125 22.5 15 1.00 0.31 3.5 10 275 22.5 15 0.85 0.37 8.0 30 275 22.5 15 1.18 0.13 8.75 10 125 7.5 45 0.63 0.66 3.0 30 125 7.5 45 1.30 0.10 3.25 10 275 7.5 45 0.83 0.34 7.25 30 275 7.5 45 1.14 0.14 8.25 20 200 15 30 1.OO 0.13 6.25 10 125 22.5 45 0.75 0.60 3.5 30 125 22.5 45 1.34 0.06 4.75 10 275 22.5 45 0.81 0.33 7.75 30 275 22.5 45 1.15 0.14 9.5 4.5 200 15 30 0.16 0.91 4.0 35.5 200 15 30 1.10 0.08 6.25 20 83.9 15 30 0.74 0.63 2.75 20 316 15 30 1.03 0.10 9.0 20 200 3.4 30 1.06 0.08 5.75 20 200 26.6 30 1.08 0.11 7.5 20 200 15 6.8 1.01 0.12 6.0 20 200 15 53.2 1.03 0.12 5.75 20 200 I5 30 1.03 0.16 5.75 No........ formulation number kn....... compaction force during the tableting process Na-alg... sodium alginate tab1... microbial cell count decrease during tableting (log units) 2 h... microbial cell count decrease during incubation in 0.04 N for 2h (log units) hours... disintegration time in the intestinal fluid (hours) Loss of viable bacteria due to tableting Results and Discussion As shown by the analysis of the central composite design, the loss of viable bacteria was dependent on the compaction force. HPMCAS and ~ vicel~, but independent of the content of sodium alginate. The con~paction force had the greatest influence: the loss of viable cells was least when a low con~paction force was applied. Upon raising of the compaction force from 10 to 30 kn. microbial cell count reduction reaches a maximum. Results suggest that an extremely high compaction force of 35.5 kn leads to a similar cell count reduction as a compaction force of 30 kn. The loss of viable cells was also smaller applying a smaller content of HPMCAS. The content of HPMCAS had no influence when a high compaction force was used. The microbial cell count reduction also decreased by lowering the contcnt of ~vicel@. 'Influences of thc relevant factors on the loss of bacteria due to tahleting are shown in Figure 1

252 M. Stadler andh. Viernstein: Figure 1: Microbial cell count reduction caused by tableting - main effects of the relevant factors (C: force: compaction force) C. force : -- HPMCAS Avicel Interactions of the factors HPMCAS and compaction force are illustrated in Figure 2. This figure shows the microbial cell count reductions observed when tablets were prepared by a compaction force between 10 kn and 30 kn, with a content of HPMCAS between 120 mg and 275 mg. Tablets manufactured with a compaction force of 30 kn and with a high HPMCAS content show the highest loss of viable cells during the tableting process. Figure 2: Response surface plot for the effects of the compaction force and the amounts of HPMCAS on the loss of viable bacteria during tablet production.i Compaction force (kn)

Tablet Formulations of Viable Lactic Acid Bacteria Gastric juice resistance Gastric juice resistance of the formulations was higher, when tablets had been prepared with a high compaction force or a mediumhigh amount of HPMCAS. The results of the orthogonal design suggest that the use of compaction forces between 30 kn and 35.5 kn or HPMCAS contents between 275 mg and 316 mg per tablet result in similar microbial cell count decreases, showing that extremely high settings of these two variables are not essential for reaching good gastric juiceresistance. ~vicel@ content had only little influence, while sodium alginate did not affect the survival rate of the bacteria during the simulated transit through the stomach. Figure 3 shows the main effects of the factors investigated. Figure 3: Microbial cell count reduction caused by incubation in artificial gastric juice - main effects of the relevant factors (C. force: compaction force) C. force HPMCAS Avicel As shown in Figure 4, gastric juice-resistance was determined of tablets manufactured by a compaction force between 10 kn and 30 kn, applying amounts of HPMCAS between 120 mg and 280 mg per tablet. Formulations prepared with high compaction forces (> 20 kn) applying high amounts of HPMCAS (> 200 mg) show the slightest loss of viable cells during incubation in 0.04N HC1 (less than 0.2 log units after incubation for two hours). In summary of the results presented so far, the effects of the experimental factors, compaction force and content of HPMCAS on the loss of viable bacteria due to tableting, and on the loss during incubation in gastric juice were opposite, suggesting that comparable counts of viable bacteria, from 0,7x to 2,0x109, as determined in vitro, would reach the intestine after administration of a tablet irrespective of the experimental settings for tablet preparation: tablets containing high amounts of HPMCAS and compacted by high compaction forces showed the best gastric juice resistance, but the highest loss of viable bacteria during tablet preparation. Tablets prepared by application of low compaction forces, with low contents of HPMCAS showed the smallest loss of viable cells during tableting, but the highest loss of viable cells during simulated gastric transit. Therefore, the disintegration time in artificial intestinal fluid is a variable of considerable interest.

M. Stadler andh. Viernstein: Figure 4: Response surface plot for the effects of the compaction force and the content of HPMCAS on resistance to gastric juice 2 Compaction force (kn) Disintegration time in artificial intestinal fluid Each parameter influenced the disintegration time in the intestinal fluid, but no interactions were observed between the parameters investigated. Fast disintegration in phosphate buffer was preferred and was achieved when tablets were manufactured applying a low compaction force and low amounts of HPMCAS, sodium alginate and ~vicel~as shown in Figure 5. ~ vicel~, originally used to accelerate disintegration time, surprisingly also delays tablet disintegration in the intestinal fluid. Figure 5: Tablet disintegration time - main effects of the parameters investigated (C. force: compaction force; Algin.: sodium alginate) C. force HPMC Algin. Avicel

M. St a d I e r and H. V i e r n s t e i n : Tablet Formulations of Viable Lactic Acid... 255 The content of HPMCAS in the tablets had the greatest influence on this test parameter. Tablets prepared with HPMCAS amounts of 275 mg disintegrated after only eight hours. Formulation No. 22, compacted with the highest amount of HPMCAS of all formulations examined had the longest disintegration time, while formulation No. 2 (containing low amounts of HPMCAS) disintegrated within 2.5 hours. References I. Fernandes C.F., Shahani K.M., Amer M.A. (1987), FEMS Microbial. Rev. 46: 343 2. Sanders M.E. (1993), Advanced in Food and Nutrition Research 37: 67 3. Berrada N., Lemeland J.F., Laroche G., Thouvenot P., Piaia M, (1990), J. Dairy Sci. 74: 409 4. Kneifel W., Viernstein H., Raffalt J. (1996), PCTI AT96100212 5. Viernstein H. (2000), AT001230 U1 6. Viernstein H. (1 998), AT 1360198 A6 1 K 7. Mersch-Sundermann V. (1 989), Medizinische Mikrobiologie. Georg Thieme, Stuttgart 8. Rogosa M., Mitchell J.A., Wiseman R.F. (1 95 l), J. Appl. Bacteriol. 62: 132 9. Luftensteiner C.P., Viernstein H. (1998), Int. J. Pharm. 171: 87 Dedicated with best wishes to o.univ.-prof. Dr. W. Fleischhacker on the occasion of his 70"' birthday. Received June 2"4 2007 Accepted September Is',2001